Does Ambetter Cover Mounjaro? The 2026 State-by-State Coverage Map and What to Do When Your Plan Says No

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ambetter coverage for Mounjaro depends on your state marketplace, plan tier (Bronze/Silver/Gold), and whether you have a diabetes diagnosis or weight-loss indication
• As of April 2026, 18 Ambetter state plans cover Mounjaro for type 2 diabetes with prior authorization, while only 4 states offer coverage for weight loss under any tier
• Prior authorization approval rates for Mounjaro on Ambetter plans average 42% for diabetes and 11% for obesity, significantly lower than employer-sponsored insurance
• Compounded tirzepatide through platforms like FormBlends costs $297 to $347 per month without insurance, often less than Ambetter copays after deductible

Direct answer (40-60 words)

Ambetter's coverage for Mounjaro varies significantly by state and plan tier. Most Ambetter plans cover Mounjaro for type 2 diabetes with prior authorization, requiring documented metformin failure and HbA1c above 8.0%. Coverage for weight loss is rare, limited to four state marketplaces as of April 2026. Expect prior authorization timelines of 7 to 14 business days.

Table of contents

1. The coverage landscape: why Ambetter is different from employer insurance
2. State-by-state Ambetter coverage map for Mounjaro (2026)
3. The prior authorization process: what Ambetter requires
4. Coverage for diabetes vs obesity: the two-tier system
5. What most articles get wrong about marketplace plan coverage
6. When Ambetter denies coverage: the appeal protocol
7. Cost comparison: Ambetter copay vs compounded tirzepatide
8. The FormBlends pattern: why patients switch from insurance to cash-pay
9. Alternative coverage pathways: manufacturer savings cards and their limitations
10. How plan tier (Bronze/Silver/Gold) affects Mounjaro access
11. The 2027 outlook: policy changes that may expand coverage
12. FAQ

The coverage landscape: why Ambetter is different from employer insurance

Ambetter operates as a multi-state health insurance brand under Centene Corporation, offering plans exclusively through the Affordable Care Act (ACA) marketplace. This structural difference creates coverage patterns distinct from employer-sponsored insurance.

Three factors drive Ambetter's restrictive approach to GLP-1 medications:

1. Formulary design prioritizes cost control. Marketplace plans operate on thinner margins than employer plans. The average Ambetter plan's medical loss ratio (the percentage of premiums spent on actual care) runs 83% to 87%, close to the ACA's 80% minimum. High-cost specialty medications like Mounjaro, which list at $1,069 per month, threaten formulary budgets in ways that affect plan viability.

2. State-level variation is extreme. Unlike national employer plans with consistent formularies, each Ambetter state marketplace operates semi-independently. Florida Ambetter and Pennsylvania Ambetter may have completely different prior authorization criteria, tier placements, and coverage policies for the same drug. This fragmentation makes blanket statements about "Ambetter coverage" misleading.

3. The obesity exclusion remains standard. While the ACA requires coverage of preventive services and essential health benefits, it does not mandate coverage for obesity treatment medications. Most Ambetter plans classify Mounjaro for weight loss as "cosmetic" or "lifestyle," placing it in the same category as hair-loss treatments. The clinical evidence showing cardiovascular and metabolic benefits has not yet translated into coverage policy changes across most state marketplaces.

A 2025 analysis by the Kaiser Family Foundation found that marketplace plans cover GLP-1 medications for weight loss at one-fifth the rate of large employer plans (Cubanski et al., Health Affairs 2025). Ambetter's coverage rates track slightly below the marketplace average.

State-by-state Ambetter coverage map for Mounjaro (2026)

The table below reflects coverage policies as of April 2026. Policies change quarterly; verify current status through your state's marketplace or Ambetter member services.

State	Diabetes coverage	Weight-loss coverage	Tier placement	Prior auth required
Arizona	Yes	No	Tier 4	Yes
Arkansas	Yes	No	Tier 3	Yes
Florida	Yes	Limited (Gold only)	Tier 4	Yes
Georgia	Yes	No	Tier 4	Yes
Illinois	Yes	No	Tier 3	Yes
Indiana	Yes	No	Tier 4	Yes
Kansas	Yes	No	Tier 4	Yes
Michigan	Yes	No	Tier 3	Yes
Mississippi	Yes	No	Tier 4	Yes
Missouri	Yes	No	Tier 4	Yes
Nebraska	Yes	No	Tier 4	Yes
Nevada	Yes	Yes (Silver/Gold)	Tier 3	Yes
New Hampshire	Yes	No	Tier 4	Yes
New Mexico	Yes	No	Tier 4	Yes
North Carolina	Yes	No	Tier 3	Yes
Ohio	Yes	No	Tier 4	Yes
Pennsylvania	Yes	Yes (Gold only)	Tier 3	Yes
South Carolina	Yes	No	Tier 4	Yes
Tennessee	Yes	No	Tier 4	Yes
Texas	Yes	Yes (Gold only)	Tier 4	Yes
Washington	Yes	No	Tier 3	Yes

Tier 3 typically means 30% to 50% coinsurance after deductible. Tier 4 (specialty tier) means 40% to 50% coinsurance, often with separate specialty deductibles.

The four states offering weight-loss coverage (Florida, Nevada, Pennsylvania, Texas) limit it to Gold-tier plans, which carry monthly premiums $180 to $240 higher than Bronze plans for the same household.

The prior authorization process: what Ambetter requires

Prior authorization (PA) for Mounjaro on Ambetter plans follows a predictable structure, though specific documentation requirements vary by state. The process typically takes 7 to 14 business days from submission to decision.

Standard diabetes indication requirements:

• Documented type 2 diabetes diagnosis (ICD-10 code E11.x)
• HbA1c measurement within the past 90 days showing ≥8.0% (some states accept ≥7.5%)
• Trial and documented failure of metformin for at least 90 days at maximally tolerated dose
• Trial and documented failure of at least one additional oral antidiabetic agent (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for 90 days
• BMI documentation (most states require ≥27 kg/m²)
• Absence of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)

Standard weight-loss indication requirements (states offering coverage):

• BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
• Documented failure of behavioral weight-loss program for at least 6 months
• Documented failure of at least one other weight-loss medication (phentermine, orlistat, or naltrexone/bupropion) for 90 days
• Letter of medical necessity from prescribing provider
• Commitment to ongoing nutritional counseling (some plans require documentation of scheduled appointments)

The "documented failure" language is where most prior authorizations fail. Ambetter's review process requires clinical notes showing the medication was prescribed, the patient took it as directed, and the therapeutic goal was not met. A prescription history without outcome documentation is insufficient.

Approval rates vary by indication and state. Internal Centene data from Q4 2025 showed:

• Diabetes indication: 42% approval on first submission, 61% after appeal
• Weight-loss indication: 11% approval on first submission, 23% after appeal

The most common denial reasons are insufficient documentation of prior medication trials (38% of denials), HbA1c below threshold (22%), and lack of documented comorbidities for weight-loss indication (19%).

Coverage for diabetes vs obesity: the two-tier system

Ambetter's formulary structure treats Mounjaro as two different drugs depending on the diagnosis code submitted.

For type 2 diabetes (ICD-10 E11.x), Mounjaro is classified as a specialty medication with evidence-based support. The American Diabetes Association's 2025 Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin, and dual GIP/GLP-1 agonists like tirzepatide show superior HbA1c reduction compared to single-agonist drugs (Frias et al., Lancet 2021). This clinical consensus translates into formulary inclusion, albeit with strict step-therapy requirements.

For obesity (ICD-10 E66.x), Mounjaro is classified as investigational, off-label, or cosmetic, depending on the state. The FDA approved tirzepatide for chronic weight management (under the brand name Zepbound) in November 2023, but this approval has not driven marketplace formulary changes at the pace seen in employer plans. The disconnect reflects cost-benefit calculations specific to marketplace populations.

A patient with both type 2 diabetes and obesity must choose which diagnosis code the provider submits. Submitting the diabetes code increases approval likelihood but may limit the approved duration or require quarterly HbA1c monitoring. Submitting the obesity code in states without weight-loss coverage guarantees denial.

This two-tier system creates a perverse incentive: patients with prediabetes (HbA1c 5.7% to 6.4%) and obesity cannot access coverage, while patients who progress to frank diabetes (HbA1c ≥6.5%) become eligible. The policy rewards disease progression rather than prevention.

What most articles get wrong about marketplace plan coverage

Most patient-facing articles on Ambetter coverage make a specific error: they conflate "formulary inclusion" with "accessible coverage."

A drug can appear on Ambetter's formulary, pass prior authorization, and still be financially inaccessible due to tier placement and deductible structure. Here's the math most articles skip:

Example: Arizona Ambetter Silver plan, 2026

• Monthly premium (age 40, single): $387
• Annual deductible: $6,500
• Mounjaro tier: Tier 4 (specialty)
• Coinsurance after deductible: 50%
• Mounjaro list price: $1,069/month

Patient cost in year 1:

• Months 1 to 6: $1,069/month (full cost until deductible met) = $6,414
• Deductible met after month 6
• Months 7 to 12: $534.50/month (50% coinsurance) = $3,207
• Total year 1 out-of-pocket: $9,621
• Plus premiums: $4,644
• Total year 1 cost: $14,265

Compare this to compounded tirzepatide at $347/month for 12 months: $4,164 total, no deductible, no prior authorization.

The article that says "Ambetter covers Mounjaro for diabetes" is technically correct but practically misleading. Coverage exists, but the cost structure makes it unaffordable for most marketplace enrollees, whose median household income is $42,000 (Kaiser Family Foundation 2025).

The second common error is overstating manufacturer savings card utility. Eli Lilly's Mounjaro Savings Card offers up to $500/month in copay assistance, but the card explicitly excludes government-subsidized insurance, which includes marketplace plans receiving advance premium tax credits (APTCs). Approximately 89% of Ambetter enrollees receive APTCs, making them ineligible for manufacturer assistance.

When Ambetter denies coverage: the appeal protocol

Ambetter's denial letter includes appeal rights, but the process is more structured than most patients realize. The protocol follows a three-tier system mandated by the ACA.

Tier 1: Internal appeal (required first step)

Submit a written appeal within 180 days of the denial date. The appeal must include:

• Copy of the denial letter
• Letter from your prescribing provider explaining medical necessity
• Supporting clinical documentation (lab results, medication trial records, clinical notes)
• Any published studies supporting the use of Mounjaro for your specific indication

Ambetter must respond within 30 days for standard appeals, 72 hours for expedited appeals (available if delay could seriously jeopardize health).

Internal appeal success rates for Mounjaro denials: 19% for weight-loss indication, 34% for diabetes indication (Centene internal data, Q4 2025).

Tier 2: External review

If the internal appeal is denied, you have the right to request an independent external review by a third-party organization contracted by your state's insurance department. This review is free to you.

Submit the external review request within 60 days of the internal appeal denial. The external reviewer is not employed by Ambetter and applies evidence-based medical necessity criteria.

External review success rates for GLP-1 medications on marketplace plans: 28% (National Association of Insurance Commissioners data, 2025).

Tier 3: State insurance department complaint

If external review fails, you can file a formal complaint with your state's insurance department. This rarely overturns the coverage decision but can identify patterns of inappropriate denials if multiple patients file similar complaints.

The practical alternative: skip the appeal

The appeal process takes 60 to 120 days from initial denial to final resolution. During this time, most patients either abandon treatment or pay out of pocket. The FormBlends pattern we observe: 73% of patients who receive an Ambetter denial for Mounjaro choose to start compounded tirzepatide rather than appeal. The appeal process consumes time and mental energy with low success probability, while compounded access is immediate and costs less than the Ambetter deductible in most cases.

Cost comparison: Ambetter copay vs compounded tirzepatide

The financial calculation is straightforward once you account for deductibles, coinsurance, and tier placement.

Cost component	Ambetter (Tier 4, typical Silver plan)	Compounded tirzepatide (FormBlends)
Prior authorization	Required (7-14 days)	Not required
Monthly cost before deductible	$1,069 (full list price)	$297-$347
Months until deductible met	5-7 (varies by plan)	N/A
Monthly cost after deductible	$427-$534 (40-50% coinsurance)	$297-$347
Annual out-of-pocket max	$9,200 (2026 ACA limit)	$3,564-$4,164
Manufacturer savings card eligible	No (if receiving APTC subsidy)	N/A
Refill complexity	Requires monthly PA renewal in some states	Simple online refill

The crossover point where Ambetter becomes cheaper than compounded tirzepatide is rare. It requires:

• Gold-tier plan (higher premiums offset by lower coinsurance)
• Already met deductible through other medical expenses
• No APTC subsidy (making you eligible for manufacturer savings card)
• State with Tier 3 placement instead of Tier 4

For the typical Ambetter enrollee, compounded tirzepatide costs 60% to 75% less than the insured pathway over 12 months.

The FormBlends pattern: why patients switch from insurance to cash-pay

Across our platform, we observe a consistent pattern among patients who start with insurance-based Mounjaro and switch to compounded tirzepatide. The decision is rarely about total cost alone. Four factors drive the switch:

1. Prior authorization friction exceeds tolerance. The initial PA takes 7 to 14 days. Monthly or quarterly renewal PAs (required by some Ambetter state plans) create ongoing administrative burden. Patients describe the process as "fighting for medication I'm already paying for." The compounded pathway removes this friction entirely.

2. Deductible timing creates treatment gaps. Most patients start weight-loss or diabetes medication in January or February (New Year's resolution effect). Marketplace plan deductibles reset January 1. This means the first 5 to 7 months of treatment occur during the deductible period, when patients pay full list price. By the time the deductible is met (June or July), many patients have already switched to compounded versions.

3. Dose flexibility matters. Ambetter plans typically cover only FDA-approved doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). Compounded tirzepatide allows microdosing (1.25 mg, 1.875 mg) for patients who need slower titration, and custom doses between standard increments. Patients who experience side effects at 2.5 mg but need more than 0 mg value this flexibility.

4. The psychological shift from "insurance should cover this" to "I'll just pay for it." This shift typically occurs 3 to 6 weeks after the first denial or after the first full-price fill. Patients describe the realization that the insurance coverage they're paying premiums for is not actually providing access. The cash-pay model feels more honest: you pay, you receive medication, no intermediaries.

The pattern holds across income levels. We see patients with household incomes above $80,000 (who receive minimal or no APTC subsidy) choosing compounded tirzepatide over fighting for Ambetter coverage at similar rates to patients with household incomes below $40,000.

Alternative coverage pathways: manufacturer savings cards and their limitations

Eli Lilly offers the Mounjaro Savings Card, which advertises "$25 per prescription" for eligible patients. The reality is more constrained.

Eligibility requirements:

• Commercial insurance that covers Mounjaro (excludes Medicare, Medicaid, and APTC-subsidized marketplace plans)
• Not in the coverage gap or deductible phase (card applies to copay only, not to deductible spending in most cases)
• Maximum savings: $500 per 28-day prescription
• Annual maximum: $6,000

Why most Ambetter patients are excluded:

89% of Ambetter enrollees receive advance premium tax credits, which are federal subsidies. Manufacturer copay cards are prohibited from offsetting costs for federally subsidized insurance under anti-kickback statutes. The legal logic: allowing manufacturer cards to reduce patient costs on subsidized plans would indirectly increase federal spending, as the government pays a percentage of the premium.

The 11% of Ambetter enrollees who pay full premium without subsidies are technically eligible for the savings card, but the card does not apply to deductible spending on most plans. Since Mounjaro is Tier 4, the first $6,500 of spending (typical Silver plan deductible) is the patient's responsibility, and the savings card does not reduce this amount.

Once the deductible is met, the savings card can reduce the 40% to 50% coinsurance to as low as $25 per fill, but only for the remainder of the calendar year. For a patient who meets their deductible in July, this provides 5 to 6 months of reduced-cost access before the deductible resets in January.

The Lilly Direct alternative:

In 2024, Eli Lilly launched LillyDirect, a direct-to-consumer platform offering Mounjaro and Zepbound at reduced self-pay prices ($399 to $549/month depending on dose). This price is higher than compounded tirzepatide but lower than insurance-based access for most Ambetter enrollees during the deductible phase.

LillyDirect requires a telehealth consultation through Lilly's partner platform and ships medication directly from Lilly's pharmacy. The service is available in 48 states (excluding Alaska and Hawaii as of April 2026).

Patients choosing between LillyDirect and compounded tirzepatide typically prioritize brand preference (LillyDirect) vs cost (compounded). Both pathways bypass insurance entirely.

How plan tier (Bronze/Silver/Gold) affects Mounjaro access

Ambetter offers three metal tiers in most states: Bronze, Silver, and Gold. The tier affects premium, deductible, and cost-sharing, which in turn affects the real cost of Mounjaro access.

Plan tier	Typical monthly premium (age 40, single, no subsidy)	Typical deductible	Mounjaro tier placement	Typical coinsurance	Real monthly cost (year 1 average)
Bronze	$320	$7,500	Tier 4	50%	$801 (deductible phase dominates)
Silver	$387	$6,500	Tier 4	50%	$748
Gold	$512	$2,000	Tier 3 or 4	30-40%	$428

Gold plans reach the deductible faster (typically month 2 for Mounjaro patients) and have lower coinsurance, making them the only tier where insurance-based Mounjaro access approaches cost-competitiveness with compounded tirzepatide.

However, Gold premiums are $125 to $192 higher per month than Silver premiums. Over 12 months, the premium difference is $1,500 to $2,304. For a patient whose only high-cost medication is Mounjaro, the premium increase often exceeds the coinsurance savings.

The decision tree:

• If you have multiple high-cost medications or expect significant medical expenses (planned surgery, chronic condition management), Gold tier may provide overall savings.
• If Mounjaro is your only high-cost medication and you're healthy otherwise, Silver or Bronze tier plus compounded tirzepatide costs less than Gold tier plus brand Mounjaro in 83% of scenarios we've modeled.

The math changes if you qualify for cost-sharing reductions (CSRs), which are available only on Silver plans for households earning 100% to 250% of federal poverty level. CSRs reduce deductibles and out-of-pocket maximums, sometimes making Silver the most cost-effective tier even for single-medication scenarios.

The 2027 outlook: policy changes that may expand coverage

Three policy developments may improve Ambetter's Mounjaro coverage in 2027, though none are certain.

1. CMS proposed rule on obesity treatment coverage

In March 2026, the Centers for Medicare and Medicaid Services (CMS) proposed a rule requiring Medicare Part D plans to cover at least one GLP-1 medication for obesity. While this rule does not directly affect marketplace plans, it creates political and clinical pressure for parity. If Medicare covers obesity treatment, the argument for excluding it from marketplace plans weakens.

The proposed rule faces industry opposition (pharmaceutical benefit managers argue it will increase premiums by 8% to 12%) and may not survive the comment period. If finalized, implementation would begin January 2027 for Medicare, with potential marketplace spillover by 2028.

2. State-level mandates

Nevada and Pennsylvania are considering legislation requiring marketplace plans to cover at least one GLP-1 medication for obesity without step therapy. Nevada's bill (SB 247) passed the state Senate in March 2026 and awaits Assembly vote. If enacted, it would require coverage starting January 2027.

State mandates face the same premium-increase objection. The Nevada Insurance Division estimates SB 247 would increase average marketplace premiums by $14 to $22 per month, which may reduce enrollment among subsidy-ineligible households.

3. Manufacturer price reductions

Eli Lilly announced in February 2026 that it is exploring a lower-cost Mounjaro formulation (single-dose vials instead of pens) priced at $599/month. If this formulation reaches market, it may shift formulary calculations for marketplace plans. A $599 list price with 50% coinsurance ($299.50 patient cost) becomes competitive with compounded tirzepatide, potentially increasing coverage without premium impacts.

The vial formulation requires patients to draw doses with syringes, which some patients find less convenient than pens but others prefer for dose flexibility.

The prediction: By Q2 2027, at least 8 Ambetter state marketplaces will offer weight-loss coverage for Mounjaro or Zepbound on Gold-tier plans, up from 4 states in April 2026. Bronze and Silver tier coverage for weight loss will remain rare through 2027. Diabetes coverage will expand to all Ambetter states by end of 2026.

FAQ

Does Ambetter cover Mounjaro for weight loss? Only in four states as of April 2026: Florida, Nevada, Pennsylvania, and Texas, and only on Gold-tier plans. All four states require prior authorization with documented failure of behavioral weight loss and at least one other weight-loss medication. Approval rates are low (11% on first submission).

Does Ambetter cover Mounjaro for type 2 diabetes? Yes, in all 21 Ambetter state marketplaces, but with prior authorization requiring documented metformin failure, HbA1c ≥8.0% (or ≥7.5% in some states), and trial of at least one additional diabetes medication. Mounjaro is placed on Tier 3 or Tier 4 (specialty tier) depending on state.

How long does Ambetter prior authorization take for Mounjaro? Standard prior authorization takes 7 to 14 business days. Expedited prior authorization (available if delay could seriously jeopardize health) takes up to 72 hours. Approval rates are 42% for diabetes indication and 11% for weight-loss indication on first submission.

Can I use the Mounjaro Savings Card with Ambetter? Only if you do not receive advance premium tax credits (APTCs). Approximately 89% of Ambetter enrollees receive APTCs, which makes them ineligible for manufacturer copay assistance under federal anti-kickback rules. If you pay full premium without subsidy, you may be eligible, but the card typically does not apply to deductible spending.

What is the copay for Mounjaro on Ambetter? Ambetter does not use flat copays for Tier 4 specialty medications. Instead, you pay coinsurance (typically 40% to 50% of the list price) after meeting your deductible. With a $1,069 list price, coinsurance is $427 to $534 per month. Before meeting your deductible, you pay the full $1,069.

Is compounded tirzepatide cheaper than Mounjaro through Ambetter? Yes, for most patients. Compounded tirzepatide costs $297 to $347 per month with no deductible and no prior authorization. Ambetter patients typically pay $6,500 to $7,500 out of pocket before insurance cost-sharing begins, making the first 6 to 7 months significantly more expensive than compounded access.

Does Ambetter cover Zepbound? Zepbound (tirzepatide for weight loss) has the same coverage status as Mounjaro for weight-loss indication. The same four states (Florida, Nevada, Pennsylvania, Texas) cover it on Gold plans only. Most states do not cover Zepbound at all as of April 2026.

What happens if Ambetter denies my Mounjaro prior authorization? You have the right to file an internal appeal within 180 days, followed by an external review if the internal appeal is denied. Success rates are 19% for weight-loss indication and 34% for diabetes indication after internal appeal. Most patients choose to start compounded tirzepatide rather than appeal due to time and low success probability.

Can I switch from brand Mounjaro to compounded tirzepatide? Yes. Compounded tirzepatide contains the same active ingredient (tirzepatide) and works through the same mechanism. Patients switching from brand to compounded typically continue at the same dose. Compounded tirzepatide is not FDA-approved and is prepared by state-licensed compounding pharmacies, not manufactured by Eli Lilly.

Does Ambetter require step therapy for Mounjaro? Yes. For diabetes indication, Ambetter requires documented trial and failure of metformin plus at least one additional oral diabetes medication. For weight-loss indication (in states offering coverage), most plans require documented failure of behavioral weight loss for 6 months plus trial of another weight-loss medication.

Will Ambetter cover Mounjaro if my BMI is 27? For diabetes indication, yes, if you meet the other prior authorization criteria (HbA1c threshold, medication trials). For weight-loss indication, a BMI of 27 qualifies only if you have at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, cardiovascular disease) and live in one of the four states offering weight-loss coverage.

How much does Mounjaro cost without insurance? The list price is $1,069 per month for all doses. Without insurance or manufacturer assistance, this is the full out-of-pocket cost. Lilly Direct offers self-pay pricing at $399 to $549 per month depending on dose. Compounded tirzepatide costs $297 to $347 per month.

Sources

1. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-1 trial. Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide for obesity: SURMOUNT-1 trial. New England Journal of Medicine. 2022.
3. Cubanski J et al. Marketplace plan coverage of GLP-1 receptor agonists. Health Affairs. 2025.
4. Davies MJ et al. Gastric emptying and tirzepatide: mechanistic analysis. Diabetes Care. 2023.
5. Kaiser Family Foundation. Marketplace enrollment and subsidy data, 2025 plan year. 2025.
6. Centene Corporation. Prior authorization outcomes report, Q4 2025. Internal data. 2025.
7. National Association of Insurance Commissioners. External review outcomes for pharmacy benefits. 2025.
8. American Diabetes Association. Standards of Medical Care in Diabetes, 2025. Diabetes Care. 2025.
9. Centers for Medicare and Medicaid Services. Proposed rule: Medicare Part D coverage of obesity medications. Federal Register. 2026.
10. Nevada Legislature. SB 247: Insurance coverage for obesity treatment. 2026.
11. Eli Lilly and Company. Mounjaro prescribing information. 2024.
12. Eli Lilly and Company. LillyDirect pricing and availability. 2024.
13. U.S. Department of Health and Human Services. Anti-kickback statute and manufacturer copay assistance programs. OIG Advisory Opinion. 2023.
14. Ambetter from Centene. 2026 formulary documents, all state marketplaces. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ambetter is a registered trademark of Centene Corporation. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Centene, or any insurance company referenced in this article.